Understand the source comparison
KLOW Multi-Target Recovery: Protocol Comparison
KPV (tripeptide) NF-κB inhibition, cytokine suppression 500–2000 mcg daily subcutaneous Anti-inflammatory effects within 7–14 days Most effective for acute flare reduction; less impact on chronic low-grade inflammation without metabolic correction Lipo C (lipo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- KPV (tripeptide)
- NF-κB inhibition, cytokine suppression
- 500–2000 mcg daily subcutaneous
- Anti-inflammatory effects within 7–14 days
- Most effective for acute flare reduction; less impact on chronic low-grade inflammation without metabolic correction
- Lipo C (lipotropic blend)
- Hepatic fat metabolism, methylation support, glutathione precursor
- 1–2 mL intramuscular 2–3×/week
- Metabolic markers improve within 4–6 weeks
- Essential for clearing hepatic lipid accumulation; limited stand-alone recovery benefit without inflammation control
- Semaglutide (Ozempic)
- GLP-1 agonism, insulin sensitivity, oxidative stress reduction
- 0.5–1.0 mg weekly subcutaneous
- Metabolic improvement within 8–12 weeks
- Dual benefit: metabolic restoration + direct anti-inflammatory effect independent of weight loss
- KLOW Combined Protocol
- Multi-pathway targeting (inflammation + metabolism + immune modulation)
- Individual components titrated to biomarker response
- Synergistic effects measurable within 12–16 weeks
- Addresses root causes simultaneously; requires medical supervision for safe titration and biomarker monitoring